On January 23, 2026, Bausch Health Companies Inc. announced the results of their Phase 3 RED-C clinical program for amorphous-rifaximin in liver cirrhosis patients to prevent hepatic encephalopathy. This event is significant for the company and reflects a positive sentiment from investors.